 CULVER CITY, Calif.--BUSINESS WIRE--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. NASDAQ: NK, a clinical-stage, natural killer cell-based therapeutics company, today announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. The FDA authorized the expansion of a currently active multi-cohort trial of the subcutaneous version of the vaccine in order to study the addition of sublingual boosts. The FDA a 